Madrigal Pharmaceuticals Appoints John C. Reed as Director to Strengthen MASH Pipeline Leadership

As competition in the MASH therapeutic space intensifies following Rezdiffra's dual FDA and European Commission approval, Madrigal Pharmaceuticals has added J&J's top R&D executive to its board, a move that signals deliberate investment in scientific governance ahead of a pivotal pipeline expansion phase.

John C. Reed, M.D., Ph.D., currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson, where he leads R&D across oncology, immunology, and neuroscience as a member of J&J's Executive Committee. His appointment to Madrigal's board brings executive-level drug discovery and translational medicine experience directly into the company's strategic oversight structure at a moment when Rezdiffra's commercial rollout is underway and a Phase 3 outcomes trial in compensated MASH cirrhosis (F4c) remains active.

Reed's career spans executive committee roles at Sanofi and Roche, as well as the presidency of Sanford-Burnham Medical Research Institute, where he built disease-focused research centers and platform technology organizations. He holds more than 130 patents and has authored over 900 scientific publications, with consistent recognition among the world's most highly cited researchers in life sciences and medicine.

For regulatory and pipeline leads tracking the MASH competitive landscape, the appointment reflects a broader pattern: companies holding first-mover approvals are reinforcing board-level scientific depth to support lifecycle management decisions, label expansion strategies, and the translational work required to advance candidates beyond fibrosis staging already addressed by approved therapies. Rezdiffra is currently indicated for MASH with moderate to advanced fibrosis (F2 to F3); the ongoing Phase 3 trial targeting F4c compensated cirrhosis represents the next material regulatory milestone for the program.

Reed's cross-functional background across global R&D strategy, drug discovery, and translational medicine positions him to contribute to decisions that will shape Madrigal's manufacturing scale-up requirements and CMC strategy as the pipeline matures toward additional regulatory submissions.

The measurable checkpoint ahead is readout from the Phase 3 compensated cirrhosis outcomes trial, which will determine whether Rezdiffra's label can be extended to the F4c population and what manufacturing and supply commitments that expansion would require.

Source: Madrigal Pharmaceuticals via GlobeNewswire, August 12, 2026.